Overview

This trial is active, not recruiting.

Condition solid tumors
Treatment humanized anti-pd-1 monoclonal antibody
Phase phase 1
Sponsor Shanghai Junshi Bioscience Co.,Ltd.
Start date March 2016
End date October 2016
Trial size 24 participants
Trial identifier NCT02857166, Junshi-JS001-ZSZL-I

Summary

The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with advanced solid tumors.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
humanized anti-pd-1 monoclonal antibody JS001
humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.

Primary Outcomes

Measure
Number of participants experiencing clinical and laboratory adverse events (AEs)
time frame: Up to 30 days post last dose

Secondary Outcomes

Measure
Anti-Drug Antibody of JS001 in Chinese patients
time frame: Cycle 1,2,3,5 Day 1 before JS001 infusion and 336 hours after last JS001 infusion, each cycle is 28 days.
Objective Response Rate (ORR)
time frame: Up to 2 approximately years
Duration of Response (DOR)
time frame: Up to 2 approximately years
Progression-Free survival (PFS)
time frame: Up to 2 approximately years
Overall Survival (OS)
time frame: Up to 2 approximately years
DLT in patients with solid tumor treated with JS001.
time frame: Cycle 1(each cycle is 28 days)
PD-1 receptor occupancy of blood
time frame: 1 year
Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb)
time frame: 1 year
Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb
time frame: 1 year
Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb Area Under the Curve [AUC]). Area Under the Curve (AUC) after single dose injection of Recombinant Humanized Anti-PD-1 Monoclonal Antibody
time frame: 1 year
t1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb
time frame: 1 year
Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb
time frame: 1 year
Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb
time frame: 1 year
Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb
time frame: 1 year
Average Plasma Concentration (Cav) of steady state after multiple dose injection of Anti-PD-1 mAb
time frame: 1 year
Degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb
time frame: 1 year
Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb
time frame: 1 year

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: 1. Histological or cytological diagnosis of advanced or recurrent adenocarcinoma of solid tumor, including adenocarcinoma of the stomach or gastro-esophageal junction, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, cholangiocarcinoma, Pancreatic ductal cell carcinoma, etc. - at least one prior chemotherapy regimen - age between 18 and 75 years, both gender - has at least one measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST V1.1) 2. life expectancy ≥ 3 months 3. ECOG performance status of 0 or 1 4. Has had last dose of chemotherapy more than 4 weeks prior to the first dose of study therapy JS001, and has recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Grade 1 or better from the AEs due to the chemotherapy. 5. Has had last administration of radioactive therapy more than 4 weeks prior to the first dose of study therapy JS001. 6. Has had last administration of immunosuppressive systemic steroid therapy (more than 10 mg/d prednisone or equal dose) more than 2 weeks prior to the first dose of study therapy JS001. 7. Has undergone major surgery that needs general anesthesia more than 4 weeks prior to the first dose of study therapy JS001. Has undergone surgery that needs local anesthesia or epidural anesthesia more than 72 hours prior to the first dose of study therapy JS001 and has already recovered from the surgery. Has undergone biopsy more than 1 hour prior to the first dose of study therapy JS001. 8. The lab examination results of the screening must fulfill all of the following: - absolute neutrophil count more than or equal to 1.5×109/ L - platelet count more than or equal to 90×109/ L - hemoglobin more than or equal to 90 g/L - creatinine less than or equal to132.6µmol/L or creatinine clearance >40 mL/min - aspartate transferase(AST) and alanine transferase(ALT) less than or equal to 3.0 ×ULN - total bilirubin less than or equal to 1.5×ULN( except for the patients with Gilbert syndrome, whose total bilirubin ,must less than or equal to 51.3µmol/L) 9. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form prior to participation in any study related activities. 10. Able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: 1. Has had antineoplastic herbal therapy within 2 weeks prior to the first dose of study therapy JS001. 2. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and receive study therapy or used an investigational device within 4 weeks of the first dose of study drug. 3. Has a medical condition that requires chronic systemic steroid therapy or on any other form of immunosuppressive medication. 4. Has a known history of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the participant has undergone potentially curative therapy with no evidence of that disease for 5 years. 5. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 6. Has interstitial lung disease OR has had a history of pneumonitis that has required oral or IV steroids. 7. Has active or suspected autoimmune disease except leukoderma,type I Diabetes, Residual hypothyroidism that induced by autoimmune thyroiditis and only requires the use of hormone replacement therapy, Or disease that rarely relapse without external stimulating factors. 8. Had prior treatment targeting PD-1: anti-PD-1,anti-PD-L1, anti-PD-L2, cytotoxic T-lymphocyte-associated protein (CTLA), or other antibodies that targeting T cell costimulatory pathway or checkpoint. 9. Has an active infection requiring systematic therapy. 10. Is positive for Human Immunodeficiency Virus (HIV). 11. Has active Tuberculosis. 12. Has known active Hepatitis B or C. 13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study. 14. Has received or will receive a live vaccine within 30 days prior to the first administration of study drug. 15. Is pregnant or breastfeeding. 16. Cannot tolerate vein puncture and / or venous access. 17. Any other conclusive medical reasons, mental illness, and / or social reasons that determined by the investigators.

Additional Information

Official title Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors
Principal investigator Ruihua Xu, MD, PhD
Description OVERVIEW This is a Phase 1, open-label, dose-escalation study of JS-001, a humanized monoclonal IgG4 antibody targeting the Programmed Death -1 (PD-1). It is estimated that 12-24 subjects with advanced or recurrent solid tumors or will be enrolled in the study. A 3+3 design will be utilized for this Phase 1 study. Four dose levels are planned and include: 0.3, 1, 3, 10 mg/kg/dose. Each of the 4 dose levels will use 2 dose schedules: single dose, repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry. The study will be the traditional 3 + 3 design with 3 or 6 subjects treated at this dose level and at all subsequent dose levels depending upon the incidence of DLTs. If no DLTs occur in a cohort of 3 subjects, a new cohort of 3 subjects will be treated at the next higher dose level. If 1 of 3 subjects in a cohort experiences a DLT, that cohort will be expanded to 6 subjects. If only 1 of the 6 subjects has a DLT, then the next cohort of 3 subjects will be treated at the next higher dose level. If 2 or more DLTs occur within a cohort, then that dose level will be above the MTD (the highest dose where no more than 1 of 6 subjects has experienced a DLT), and the previous lower (tolerated) dose level will be considered the MTD. A DLT is defined as a Grade 3 drug-related adverse event occurring within the first cycle (28 days) of dosing (excluding tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 in a single dose cohort. Tumor response will be evaluated using immune-related response criteria (irRC), WHO criteria , Response Evaluation Criteria in Solid Tumors (RECIST), immune-related RECIST, and International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphomas (for lymphomas only). In the absence of confirmed disease progression and intolerable toxicities, subjects in the single dose cohorts and multiple dose cohorts will be allowed to continue JS-001 administration with the consent of the subject. DOSAGE AND ADMINISTRATION JS-001 will be administered as a 60-minute i.v. infusion. Cohorts will include escalating dose levels of 0.3, 1, 3, 10mg/kg/dose. SAFETY EVALUATIONS Assessment of safety will be determined by vital sign measurements, clinical laboratory tests, Eastern Cooperative Oncology Group (ECOG) performance status evaluations, diagnostic imaging, physical examinations, electrocardiograms, and the incidence and severity of adverse events. Safety will also include evaluations of immune safety and immunogenicity. Particular attention will be given to adverse events that may follow enhanced T-cell activation such as dermatitis and colitis, uveitis, or other immune-related adverse events (irAEs). An irAE is a clinically significant adverse event of any organ that is associated with drug exposure, of unknown etiology, and is consistent with an immune-mediated mechanism. EFFICACY EVALUATIONS The primary efficacy endpoint is the best response rate (RR). Duration of response, progression-free survival, time to progression, and overall survival will also be analyzed. PHARMACOKINETIC EVALUATIONS Pharmacokinetic parameters include AUC, Cmax, tmax, and t½, etc. STATISTICAL METHODS The sample size for this study is not determined from power analysis. It is based on the 3+3 design for dose escalation and safety evaluation requirements. Descriptive statistics will include: mean, standard deviation, median, and minimum and maximum values for continuous variables; frequencies and percentages for categorical variables. The efficacy parameters will be summarized using descriptive statistics. All safety and pharmacokinetic parameters will be summarized using descriptive statistics.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Shanghai Junshi Bioscience Co.,Ltd..